Rupoma5 mg/5 ml

Rupoma is a second-generation (non-sedating) antihistamine indicated for:

• Seasonal and perennial allergic rhinitis (established/approved use) — relief of nasal and ocular symptoms such as sneezing, rhinorrhea, nasal itching/congestion, and itchy, watery eyes, in adults and children 2 years of age and older.
• Chronic spontaneous (idiopathic) urticaria (established/approved use) — relief of pruritus (itching) and reduction in the number and size of hives/wheals, in adults and children 2 years of age and older.

Rupoma is not approved for, and should not be used to treat, acute anaphylaxis, and it is not a substitute for epinephrine in emergency allergic reactions.

Each formulation of Rupatadine Fumarate contains rupatadine fumarate as the active ingredient, dosed to provide the stated equivalent amount of rupatadine base.

• Tablet: Rupatadine Fumarate equivalent to rupatadine 10 mg
• Oral solution: Rupatadine Fumarate equivalent to rupatadine 1 mg/mL (commonly supplied as 5 mg/5 mL)

Excipients vary by brand and formulation and may include lactose (tablets) or sucrose (oral solution); patients with relevant sugar-intolerance conditions should check the specific product's excipient list (see Contraindications).

Rupoma is a second-generation, long-acting, non-sedating antihistamine that combines selective peripheral histamine H1-receptor antagonism with platelet-activating factor (PAF) antagonist activity. It is taken orally, as a tablet or oral solution, for symptomatic relief of allergic conditions.

Because of this dual mechanism, Rupoma is often described among newer-generation antihistamines with additional anti-inflammatory, anti-allergic properties beyond simple H1-receptor blockade.

Rupoma belongs to the therapeutic class of second-generation (non-sedating) antihistamines — specifically, a selective histamine H1-receptor antagonist with additional platelet-activating factor (PAF) antagonist activity.

Rupatadine Fumarate is a potent, long-acting, selective antagonist of peripheral histamine H1-receptors. Unlike many first-generation antihistamines, it does not readily cross the blood-brain barrier in significant amounts at recommended doses, giving it a low potential for sedation.

In addition to H1-antagonism, Rupatadine Fumarate antagonizes platelet-activating factor (PAF), a mediator involved in the late-phase allergic inflammatory response. Combined H1- and PAF-antagonism is thought to underlie its efficacy against both the immediate (histamine-driven) and late (PAF/cytokine-driven) phases of allergic inflammation, including inhibition of mast-cell degranulation and reduction of certain pro-inflammatory cytokines such as TNF-alpha.

Pharmacokinetics: Rupatadine Fumarate is absorbed after oral administration and extensively metabolized in the liver, primarily via CYP3A4, to active metabolites. Elimination occurs mainly via the feces, with a smaller renal component. Onset of action is generally within 1–2 hours, and the duration of effect supports once-daily dosing.

Rupoma tablets should be swallowed whole with a glass of water, with or without food. The oral solution should be measured accurately using an appropriate oral dosing syringe or measuring cup, not a household spoon.

Take Rupoma at approximately the same time each day. If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose, in which case skip the missed dose — do not double the dose. Grapefruit juice should be avoided while taking Rupoma, as it can substantially increase drug levels (see Interactions).

Rupoma is metabolized primarily by the hepatic enzyme CYP3A4, making it susceptible to clinically significant interactions with CYP3A4 inhibitors:

• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, and similar agents): can markedly increase (several-fold) systemic exposure to Rupoma; concurrent use is contraindicated (see Contraindications).
• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole, diltiazem, azithromycin): can meaningfully increase exposure to Rupoma; concurrent use should be avoided or undertaken with caution and monitoring.
• Grapefruit juice: can increase systemic exposure to Rupoma several-fold; avoid concurrent intake.
• QT-prolonging drugs: concurrent use with drugs known to prolong the QT interval is contraindicated because of a reported risk of cardiac arrhythmia (see Contraindications).
• CNS depressants and alcohol: may enhance the sedative and psychomotor-impairing effects of Rupoma; concurrent use should be avoided, particularly before driving or operating machinery.
• Statins (e.g., simvastatin): asymptomatic increases in creatine phosphokinase have been reported with concurrent use; monitor as clinically indicated.

The most commonly reported side effects of Rupoma include:

• Somnolence/drowsiness
• Headache
• Dizziness
• Fatigue/asthenia

Less common effects include dry mouth, nausea, abdominal pain/dyspepsia, increased appetite, weight gain, arthralgia, back pain, cough, and pharyngitis.

Rare but serious: palpitations, tachycardia, and, rarely in post-marketing reports, QT-interval changes/torsade de pointes have been described. Hypersensitivity reactions, including angioedema and anaphylaxis, have also been reported post-marketing. Seek prompt medical attention for facial/throat swelling, difficulty breathing, chest palpitations, or fainting while taking Rupoma.

Pregnancy: There are no adequate and well-controlled studies of Rupoma in pregnant women. Rupoma should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Rupoma or its metabolites pass into human breast milk. Use of Rupoma during breastfeeding is generally not recommended unless a physician determines that the benefit to the mother outweighs any potential risk to the breastfed infant.

Rupoma should be used with caution in the following situations:

• Cardiac risk factors: caution in patients with hypokalemia, bradycardia, or conditions predisposing to QT-interval prolongation, given rare reports of QT changes/torsade de pointes (see Contraindications for absolute restrictions).
• CNS effects: mild sedation can occur in some patients; caution is advised when driving or operating machinery, especially if combined with alcohol or other CNS depressants (this combination should be avoided).
• Hepatic or renal impairment: use is not recommended, as clinical experience is limited and drug levels may increase (see Use in Special Populations).
• Elderly patients: use with caution given limited data in patients over 65 years.
• Excipient-related restrictions: tablets containing lactose should be avoided in patients with galactose intolerance or glucose-galactose malabsorption; oral solution containing sucrose should be used with caution in patients with fructose intolerance or sucrase-isomaltase deficiency.

Rupoma is not an antibiotic and has no role in treating infections.

Overdose with Rupoma may cause increased somnolence and other exaggerated pharmacologic effects. In clinical safety studies, doses up to 100 mg daily for six days were generally well tolerated, but individual sensitivity may vary.

There is no specific antidote for Rupoma overdose. If overdose is suspected, seek immediate medical attention or contact a poison control center. Management is supportive and symptomatic; inducing vomiting is not generally recommended.

Store Rupoma at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Rupoma is approved for children 2 years and older using weight-based oral-solution dosing; it is not recommended for children under 2 years (see Pediatric Uses).

Elderly: limited clinical data are available in patients over 65 years; use with caution.

Hepatic impairment: use of Rupoma is not recommended due to limited clinical experience and the potential for increased drug exposure.

Renal impairment: use of Rupoma is not recommended due to limited clinical experience in this population.

Pregnancy and lactation: see the Pregnancy and Lactation section.

The duration of treatment with Rupoma depends on the clinical indication:

• For seasonal allergic rhinitis, treatment is typically continued for the duration of allergen/pollen exposure.
• For perennial allergic rhinitis and chronic urticaria, longer-term daily use may be appropriate, guided by ongoing symptom control; clinical trials have evaluated continuous use for up to 6 weeks in children and longer periods in adults.

Treatment duration with Rupoma should be reviewed periodically by the prescribing physician, and use should be reassessed if symptoms resolve or fail to improve.

Rupatadine Fumarate is classified as:

• Antihistamine
• Second-generation (non-sedating) H1-receptor antagonist
• Platelet-activating factor (PAF) antagonist

Rupatadine Fumarate acts as a selective antagonist at peripheral histamine H1-receptors, blocking histamine-mediated allergic symptoms such as itching, sneezing, and rhinorrhea, without significant central sedative activity at recommended doses. It additionally antagonizes platelet-activating factor (PAF), a mediator of the late-phase allergic response, and reduces mast-cell-mediated release of inflammatory mediators, giving Rupatadine Fumarate combined anti-histaminic and anti-inflammatory, anti-allergic activity.

Rupoma is approved for use in children 2 years of age and older for allergic rhinitis and chronic urticaria, using the oral solution formulation with weight-based dosing (2.5 mg once daily for 10–25 kg; 5 mg once daily for ≥25 kg).

Tablets are not recommended for children under 12 years; the oral solution should be used instead for younger children who require dosing. Safety and efficacy of Rupoma in children under 2 years of age have not been established, and use in this age group is not recommended. Long-term pediatric safety data beyond several weeks of continuous use are limited.